Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Apr;74(5):563-78.
doi: 10.1007/s40265-014-0197-5.

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): A Review of Its Use in Patients With Moderate to Severe Spasticity Due to Multiple Sclerosis

Affiliations
Review

Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): A Review of Its Use in Patients With Moderate to Severe Spasticity Due to Multiple Sclerosis

Yahiya Y Syed et al. Drugs. .

Abstract

Delta-9-tetrahydrocannabinol (THC)/cannabidiol (CBD) [Sativex®] is an oromucosal spray formulation that contains principally THC and CBD at an approximately 1:1 fixed ratio, derived from cloned Cannabis sativa L. plants. The main active substance, THC, acts as a partial agonist at human cannabinoid receptors (CB1 and CB2), and thus, may modulate the effects of excitatory (glutamate) and inhibitory (gamma-aminobutyric acid) neurotransmitters. THC/CBD is approved in a number of countries, including Germany and the UK, as an add-on treatment for symptom improvement in adult patients with moderate to severe spasticity due to multiple sclerosis who have not responded adequately to other anti-spasticity medication and who demonstrate clinically significant improvement in spasticity-related symptoms during an initial trial of therapy. In the largest multinational clinical trial that evaluated the approved THC/CBD regimen in this population, 12 weeks' double-blind treatment with THC/CBD significantly reduced spasticity severity (primary endpoint) compared with placebo in patients who achieved a clinically significant improvement in spasticity after 4 weeks' single-blind THC/CBD treatment, as assessed by a patient-rated numerical rating scale. A significantly greater proportion of THC/CBD than placebo recipients achieved a ≥ 30% reduction (a clinically relevant reduction) in spasticity severity. The efficacy of THC/CBD has been also shown in at least one everyday clinical practice study (MOVE 2). THC/CBD was generally well tolerated in clinical trials. Dizziness and fatigue were reported most frequently during the first 4 weeks of treatment and resolved within a few days even with continued treatment. Thus, add-on THC/CBD is a useful symptomatic treatment option for its approved indication.

Similar articles

See all similar articles

Cited by 19 articles

See all "Cited by" articles

References

    1. Eur J Neurol. 2011 Sep;18(9):1122-31 - PubMed
    1. CNS Drugs. 2011 Mar;25(3):187-201 - PubMed
    1. Neurol Res. 2010 Jun;32(5):451-9 - PubMed
    1. Expert Rev Neurother. 2013 Feb;13(3 Suppl 1):9-13 - PubMed
    1. Int J Neurosci. 2014 Sep;124(9):652-6 - PubMed

MeSH terms

LinkOut - more resources

Feedback